Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $3,165,350.10 in Stock

Key Points

• Insider Johannes Jacob Piete Kastelein sold multiple large blocks of NAMS shares — most recently 104,467 shares on March 5 at $30.30 for $3.17M — cutting his position by 60.12%; the January–March sales total about $10.9M.
• Shares traded up 3.0% to $30.77, but the company reported a quarterly loss (EPS -$0.63) that missed estimates and remains unprofitable; analysts still give a consensus "Moderate Buy" with an average target of $47.10.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 104,467 shares of NewAmsterdam Pharma stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $30.30, for a total value of $3,165,350.10. Following the transaction, the insider owned 69,302 shares of the company's stock, valued at $2,099,850.60. The trade was a 60.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Johannes Jacob Piete Kastelein also recently made the following trade(s):

• On Monday, March 9th, Johannes Jacob Piete Kastelein sold 101,409 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $30.29, for a total value of $3,071,678.61.
• On Friday, March 6th, Johannes Jacob Piete Kastelein sold 94,124 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $30.32, for a total value of $2,853,839.68.
• On Friday, February 20th, Johannes Jacob Piete Kastelein sold 45,481 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.31, for a total value of $1,605,934.11.
• On Monday, January 5th, Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.25, for a total value of $199,500.00.

NewAmsterdam Pharma Stock Up 3.0%

Shares of NASDAQ:NAMS traded up $0.91 during trading on Monday, hitting $30.77. 761,265 shares of the stock traded hands, compared to its average volume of 827,191. The company has a fifty day moving average price of $33.48 and a two-hundred day moving average price of $33.32. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $42.00. The company has a market cap of $3.54 billion, a price-to-earnings ratio of -17.79 and a beta of 0.04.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.23). The firm had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. On average, equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently made changes to their positions in NAMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in NewAmsterdam Pharma during the first quarter worth about $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of NewAmsterdam Pharma by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company's stock valued at $5,898,000 after purchasing an additional 34,563 shares during the period. Teacher Retirement System of Texas acquired a new position in shares of NewAmsterdam Pharma in the second quarter valued at approximately $212,000. Bank of New York Mellon Corp acquired a new position in shares of NewAmsterdam Pharma in the second quarter valued at approximately $6,392,000. Finally, Geode Capital Management LLC increased its stake in NewAmsterdam Pharma by 15.9% during the 2nd quarter. Geode Capital Management LLC now owns 99,457 shares of the company's stock worth $1,800,000 after buying an additional 13,629 shares during the period. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. The Goldman Sachs Group boosted their price objective on NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a "neutral" rating in a research report on Tuesday, December 2nd. HC Wainwright raised shares of NewAmsterdam Pharma to a "strong-buy" rating in a report on Thursday, February 19th. Weiss Ratings reissued a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Needham & Company LLC boosted their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a "buy" rating in a research report on Wednesday, February 18th. Finally, Royal Bank Of Canada upped their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an "outperform" rating in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $47.10.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.